-+ 0.00%
-+ 0.00%
-+ 0.00%

Takeda's Phase 3 Trial Of Oveporexton's Data Published In New England Journal Of Medicine To Treat Narcolepsy Type 1; Oveporexton Generally Well-Tolerated With Consistent Safety Profile

Benzinga·09/09/2026 12:26:59
Listen to the news

Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1.